Thomas Collet, Ph.D., is an experienced senior business leader and strategic thinker with a passion for innovation. Based in Cambridge, Mass., he specializes in helping firms in the life science and medical industries develop and commercialize new products and technologies. “I look for companies working on products that, if successful, will make a material difference in people’s lives,” he says.
The two-year project focused on reducing the use of extended-fraction radiation therapy to treat pain from incurable cancer that had spread to patients’ bones. Once a standard practice, the American Society for Radiation Oncology has recommended against the routine use of extended-fraction radiation to relieve pain from bone metastases, especially more than 10 treatments.
The University of Michigan is one of eight sites around the country that will enroll patients in a clinical trial to evaluate the safety and efficacy of a technology that uses ultrasound to treat liver tumors.
Having an Erdheim-Chester Disease (ECD) referral center located in this region will help the 12 Michigan-based patients currently registered with ECDGA.
ApoE, an apolipoprotein known to play roles in cardiovascular disease and Alzheimer’s, is elevated in the blood of people with pancreatic adenocarcinoma, according to this new research.
The University of Michigan Rogel Cancer Center has named two new assistant directors, Elena Stoffel, M.D., M.P.H. and Lawrence An, M.D., to help facilitate and enhance its community outreach and engagement efforts.
Research suggests stopping the interaction between KRAS and the protein AGO2 slowed tumor growth in mouse models and lead to better treatment for non-small cell lung cancer.
MENU